Entera Bio Past Earnings Performance

Past criteria checks 0/6

Entera Bio has been growing earnings at an average annual rate of 2.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 32.7% per year.

Key information

2.3%

Earnings growth rate

24.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-32.7%
Return on equity-100.0%
Net Margin-14,975.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Jul 12
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

May 31
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Feb 15
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Oct 13
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Aug 11

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Jun 10
We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Jan 21
Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06
We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05
Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Entera Bio EPS misses by $0.22

Nov 19

Revenue & Expenses Breakdown

How Entera Bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ENTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-944
31 Mar 240-944
31 Dec 230-945
30 Sep 230-1065
30 Jun 230-1165
31 Mar 230-1175
31 Dec 220-1386
30 Sep 220-1477
30 Jun 220-1478
31 Mar 220-1477
31 Dec 211-1267
30 Sep 211-1255
30 Jun 211-1055
31 Mar 210-1156
31 Dec 200-1156
30 Sep 200-1157
30 Jun 200-1357
31 Mar 200-1157
31 Dec 190-1147
30 Sep 191-1047
30 Jun 191-1247
31 Mar 191-938
31 Dec 181-1039
30 Sep 180-1158
30 Jun 180-1076
31 Mar 180-1385
31 Dec 170-1193
30 Sep 170-862
30 Jun 170-643
31 Mar 170-433
31 Dec 160-133

Quality Earnings: ENTX is currently unprofitable.

Growing Profit Margin: ENTX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ENTX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare ENTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: ENTX has a negative Return on Equity (-100.05%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies